Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2007

Bavarian Nordic Achieves $25M Milestone from the HHS

  • Bavarian Nordic reports that it has reached another milestone in its agreement with the U.S. government and will thus receive $25 million. In June, the HHS contracted the firm to manufacture and deliver 20 million doses of its smallpox vaccine in a deal potentially worth $1.6 billion.

    This year, Bavarian Nordic has received $100 million in relation to this deal. The firm was reportedly paid $50 million in advance. It also received another $25 million milestone fee just three weeks ago.

    Next year, Bavarian Nordic expects to receive yet another milestone payment of $25 million.
    Imvamune is based on the Modified Vaccinia Ankara virus, a live virus but one that does not replicate in the body, according to the company.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »